Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial - PubMed (original) (raw)
Clinical Trial
. 2003 Dec 17;95(24):1833-46.
doi: 10.1093/jnci/djg119.
Affiliations
- PMID: 14679153
- DOI: 10.1093/jnci/djg119
Clinical Trial
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
International Breast Cancer Study Group (IBCSG) et al. J Natl Cancer Inst. 2003.
Abstract
Background: Although chemotherapy and ovarian function suppression are both effective adjuvant therapies for patients with early-stage breast cancer, little is known of the efficacy of their sequential combination. In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone.
Methods: From March 1990 through October 1999, 1063 patients stratified by estrogen receptor (ER) status and radiotherapy plan were randomly assigned to receive goserelin for 24 months (n = 346), six courses of "classical" CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or six courses of classical CMF followed by 18 months of goserelin (CMF --> goserelin; n = 357). A fourth arm (no adjuvant treatment) with 46 patients was discontinued in 1992. Tumors were classified as ER-negative (30%), ER-positive (68%), or ER status unknown (3%). Twenty percent of patients were aged 39 years or younger. The median follow-up was 7 years. The primary outcome was disease-free survival (DFS).
Results: Patients with ER-negative tumors achieved better disease-free survival if they received CMF (5-year DFS for CMF = 84%, 95% confidence interval [CI] = 77% to 91%; 5-year DFS for CMF --> goserelin = 88%, 95% CI = 82% to 94%) than if they received goserelin alone (5-year DFS = 73%, 95% CI = 64% to 81%). By contrast, for patients with ER-positive disease, chemotherapy alone and goserelin alone provided similar outcomes (5-year DFS for both treatment groups = 81%, 95% CI = 76% to 87%), whereas sequential therapy (5-year DFS = 86%, 95% CI = 82% to 91%) provided a statistically nonsignificant improvement compared with either modality alone, primarily because of the results among younger women.
Conclusions: Premenopausal women with ER-negative (i.e., endocrine nonresponsive), lymph node-negative breast cancer should receive adjuvant chemotherapy. For patients with ER-positive (i.e., endocrine responsive) disease, the combination of chemotherapy with ovarian function suppression or other endocrine agents, and the use of endocrine therapy alone should be studied.
Comment in
- Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.
Pater JL, Parulekar WR. Pater JL, et al. J Natl Cancer Inst. 2003 Dec 17;95(24):1811-2. doi: 10.1093/jnci/djg133. J Natl Cancer Inst. 2003. PMID: 14679143 Review. No abstract available.
Similar articles
- Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Karlsson P, et al. Ann Oncol. 2011 Oct;22(10):2216-26. doi: 10.1093/annonc/mdq735. Epub 2011 Feb 16. Ann Oncol. 2011. PMID: 21325445 Free PMC article. Clinical Trial. - Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG). International Breast Cancer Study Group (IBCSG). J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65. doi: 10.1093/jnci/94.14.1054. J Natl Cancer Inst. 2002. PMID: 12122096 Clinical Trial. - Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group Trial VIII. Bernhard J, et al. J Clin Oncol. 2007 Jan 20;25(3):263-70. doi: 10.1200/JCO.2005.04.5393. Epub 2006 Dec 11. J Clin Oncol. 2007. PMID: 17159194 Clinical Trial. - Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI. Pritchard KI. Oncology (Williston Park). 2009 Jan;23(1):27-33. Oncology (Williston Park). 2009. PMID: 19283918 Review. - LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R, Hamilton A, Beith J. Sharma R, et al. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Cochrane Database Syst Rev. 2008. PMID: 18843661 Updated. Review.
Cited by
- The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
Zhang A, Wang X, Fan C, Mao X. Zhang A, et al. Front Endocrinol (Lausanne). 2021 Nov 3;12:687244. doi: 10.3389/fendo.2021.687244. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34803903 Free PMC article. Review. - A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, Ohtake T, Fujii T, Ohashi Y. Kurebayashi J, et al. Breast Cancer. 2021 May;28(3):684-697. doi: 10.1007/s12282-020-01205-w. Epub 2021 Feb 27. Breast Cancer. 2021. PMID: 33638810 Free PMC article. Clinical Trial. - Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer.
Turnbull AK, Patel S, Martinez-Perez C, Rigg A, Oikonomidou O. Turnbull AK, et al. Breast Cancer Res Treat. 2021 Feb;186(1):237-245. doi: 10.1007/s10549-020-05951-5. Epub 2020 Oct 12. Breast Cancer Res Treat. 2021. PMID: 33047206 Free PMC article. - Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Bui KT, et al. Cochrane Database Syst Rev. 2020 Mar 6;3(3):CD013538. doi: 10.1002/14651858.CD013538. Cochrane Database Syst Rev. 2020. PMID: 32141074 Free PMC article. - Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.
Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, López-Muñoz E, Guillén N, Olivo-Marin JC, Aguilar-Rojas A. Huerta-Reyes M, et al. Front Oncol. 2019 Oct 1;9:943. doi: 10.3389/fonc.2019.00943. eCollection 2019. Front Oncol. 2019. PMID: 31632902 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical